FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

		00540
Vashington,	D.C.	20549

STATEMENT OF	CHANGES IN	BENEFICIAL	OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-02									
Estimated average burden									
hours per response	: 0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Tross Stuart A						2. Issuer Name and Ticker or Trading Symbol MANNKIND CORP [MNKD]								(Chec	k all app Direc	ctor		10% O	wner
(Last)	(Fir	,	Middle)		3. Date of Earliest Transaction (Month/Day/Year) 05/17/2024								X	below)			Other (specify below) Workpl Officer		
(Street) DANBU	RY CT	0	6810		4. If <i>I</i>	Amend	ment,	Date of	f Origina	ıl Filed	d (Month/Da	y/Year)		6. Indi Line) X	Form	Joint/Grou filed by On filed by Mo	e Rep	orting Pers	on
(City)	(St	State) Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.																	
		Table	I - No	n-Deriva	tive S	Secu	rities	Acq	uired,	Dis	posed of	, or Be	enefic	cially	/ Own	ed			
			2. Transac Date (Month/Da	ay/Year) Exec		Deemed ecution Date, ny onth/Day/Year)				es Acquired (A) Of (D) (Instr. 3, 4		and Securit		ies cially Following	Form (D) o	n: Direct r Indirect estr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
						Code	v	Amount	(A) or (D)	Pric	Trans		ction(s) 3 and 4)			(111511.4)			
Common	Stock, \$0.0	1 Par Value		05/17/2	2024	2024			A ⁽¹⁾		77,420	A	\$4	1.59	1,223,124			D	
Common	Common Stock, \$0.01 Par Value 05/17/20					2024		F ⁽²⁾		62,056	D	D \$4.5		.59 1,161,068			D		
Common Stock, \$0.01 Par Value 05/18/2					2024				F ⁽²⁾ 6,130		D	\$4	1,154,9		54,938 D		D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	emed ion Date, /Day/Year)	4. Transa Code (8)				6. Date Exercisable ar Expiration Date (Month/Day/Year)		te	7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		De Se (In:	Price of rrivative curity estr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code V (A) (D)			Date Exercis	able	Expiration Date		Amount or Number of Shares							

Explanation of Responses:

05/21/2024 /s/ Stuart A. Tross

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{1.} A previously reported restricted stock unit award granted on May 18, 2021 vested on May 17, 2024 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on May 17, 2024 was not less than the closing price on May 17, 2021 and (ii) MannKind's total shareholder return (TSR) over the period from May 18, 2021 to May 17, 2024 was at the 74.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 198% of target, resulting in a total share delivery of 156,420 shares. The acquisition of 79,000 shares pursuant to the restricted stock award was reported in Table I of the Form 4 filed by the Reporting Person on May 18, 2021.

^{2.} Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.